Tolvaptan in Later-Stage Polycystic Kidney Disease

Affiliations

Comment

Vicente E Torres et al. N Engl J Med. 2018.

. 2018 Feb 1;378(5):489-490.

doi: 10.1056/NEJMc1716478.

No abstract available

Conflict of interest statement

No potential conflict of interest relevant to this letter was reported.

Tolvaptan in Later-Stage Polycystic Kidney Disease.
De Tymowski C, Legrand M. De Tymowski C, et al. N Engl J Med. 2018 Feb 1;378(5):488. doi: 10.1056/NEJMc1716478. N Engl J Med. 2018. PMID: 29394474 No abstract available.
Tolvaptan in Later-Stage Polycystic Kidney Disease.
Pazmiño PA. Pazmiño PA. N Engl J Med. 2018 Feb 1;378(5):488-9. doi: 10.1056/NEJMc1716478. N Engl J Med. 2018. PMID: 29394475 No abstract available.

1. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377: 1930–42. - PubMed
1. Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295–301. - PubMed
1. Takahashi N, Kondo Y, Ito O, Igarashi Y, Omata K, Abe K. Vasopressin stimulates Cl- transport in ascending thin limb of Henle’s loop in hamster. J Clin Invest 1995; 95: 1623–7. - PMC - PubMed
1. Boertien WE, Meijer E, de Jong PE, et al. Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis 2015; 65: 833–41. - PubMed
1. Aoyagi T, Izumi Y, Hiroyama M, et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol 2008; 295: F100–F107. - PubMed